NTLA — Intellia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1652130 ·
Last close
$12.60
Market Cap
$1.77B
52W High
$28.25
52W Low
$7.95
ADV30
4,748,746
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 7,659,000 | — | -112,760,000 | -106,634,000 | 857,164,000 | 106,128,000 | 129,458,000 |
| Mar 2026 | 15,048,000 | — | -100,532,000 | -96,231,000 | 758,779,000 | 134,697,000 | 137,840,000 |
| Dec 2025 | 23,017,000 | — | -98,710,000 | -95,786,000 | 842,127,000 | 155,464,000 | 170,733,000 |
| Sep 2025 | 13,782,000 | — | -111,477,000 | -101,324,000 | 925,275,000 | 193,389,000 | 176,853,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-346,643,000
Investing CF
$-48,469,000
Financing CF
$346,519,000
CapEx
$-2,043,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.36
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,792,959,000
Inventory
—
Receivables
$7,321,000
ST Investments
$331,631,000
EBIT TTM
$-423,479,000
Pretax Income TTM
$-399,975,000
Interest Exp TTM
—
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,506,000
EBITDA
$-414,400,000
Free Cash Flow
$-249,825,376
Enterprise Value
$1,280,738,432
Total Cash
$437,759,008
Total Debt
$73,410,000
Shares Out
140,126,693
Trailing EPS
$-3.34
Book Value
$5.20
ROE
-55.4%
ROA
-30.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,671,000 | -440,990,000 | -412,694,000 | 842,127,000 | 170,733,000 | 671,394,000 | -394,736,000 |
| Dec 2024 | 57,877,000 | -534,263,000 | -519,021,000 | 1,191,015,000 | 319,059,000 | 871,956,000 | -348,880,000 |
| Dec 2023 | 36,275,000 | -515,291,000 | -481,192,000 | 1,300,977,000 | 250,808,000 | 1,050,169,000 | -394,086,000 |
| Dec 2022 | 52,121,000 | -458,164,000 | -474,186,000 | 1,520,114,000 | 284,530,000 | 1,235,584,000 | -333,287,000 |
TTM Snapshot
Revenues TTM
$66,092,000
NetIncome TTM
$-394,596,000
OpCashFlow TTM
—
Assets (Latest)
$758,779,000
Forward EPS
$-2.60
Max Pain — expiry 2026-10-16
max pain strike: $12.00 · spot: $12.60 · call oi: 14,087 · put oi: 5,294
Expected Move to 2026-10-16:
±$1.25
(9.92%) —
implied range
$11.35 –
$13.85
· ATM straddle on $13.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABSI | Absci Corp | $1.53B | $8.94 | — |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | $29.30 | — |
| NEOG | NEOGEN CORP | $2.55B | $11.71 | — |
| QDEL | QuidelOrtho Corp | $851.02M | $12.41 | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $739.87M | $7.19 | — |
News headlines (Yahoo Finance, 1h cache)
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-06 12:16 · Yahoo
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
2026-09-29 13:00 · Yahoo
Could This Cathie Wood Stock Soar in 2027?
2026-09-27 16:50 · Yahoo
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 21:49 · Yahoo
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy
2026-09-22 13:20 · Yahoo
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
2026-09-19 04:02 · Yahoo
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
2026-09-10 18:42 · Yahoo
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
2026-09-08 14:08 · Yahoo
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
2026-09-18 15:38 · Yahoo
Why Cathie Wood Is Taking Profits on AMD Stock
2026-10-07 14:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.